{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:16:46Z","timestamp":1762881406962,"version":"3.45.0"},"reference-count":20,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["16\/145\/01"],"award-info":[{"award-number":["16\/145\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n There is insufficient evidence on the effectiveness of different antidepressants in Parkinson\u2019s disease. This trial was commissioned to provide robust evidence regarding the effectiveness of a tricyclic and a selective serotonin reuptake inhibitor on depression in people with Parkinson\u2019s disease.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the clinical effectiveness and cost-effectiveness of the tricyclic nortriptyline and the selective serotonin reuptake inhibitor escitalopram in addition to standard psychological care in the National Health Service in the treatment of depression in Parkinson\u2019s disease.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Forty-seven-month, multisite, three-arm, placebo-controlled, double-blind, randomised controlled trial, with an internal pilot phase. Four hundred and eight patients with a 1\u2005:\u20051\u2005:\u20051 randomisation between placebo, nortriptyline and escitalopram. The pilot study aimed to recruit 46 participants in the first 6 months from 10 sites to decide whether the trial is feasible.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were treated with nortriptyline (target dose 100\u2005mg in patients 65 and under, or 50\u2005mg in patients over 65 or those with hepatic impairment), escitalopram (target dose 20\u2005mg in patients 65 and under, or 10\u2005mg in patients over 65 or those with hepatic impairment) or placebo, in addition to available standard psychological care.<\/jats:p>\n <\/jats:sec>\n \n Outcomes<\/jats:title>\n The primary outcome measure was the Beck Depression Inventory-II at 8 weeks. Secondary outcomes included clinician- and patient-reported outcomes, with safety summaries.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Fifty-two patients were recruited and randomised to receive either nortriptyline, escitalopram, or a placebo-matched tablet. This was effectively the internal pilot period, with the trial being truncated at this point. There was a reduction in Beck Depression Inventory-II scores between baseline to week 8 in all arms. In the placebo arm, this was from a mean of 24.3 (SD 7.8) at baseline to 15.7 (SD 5.8) at week 8, in the nortriptyline arm from 20.5 (SD 3.8) to 12.6 (SD 8.1), and in the escitalopram arm from 23.3 (SD 8.0) to 14.6 (SD 8.4). The reduction in Beck Depression Inventory-II scores was not significantly different between either of the two active arms and the placebo arm, with a mean change of \u22123.1 (95% confidence interval \u22128.66 to 2.53,\n p<\/jats:italic>\n \u2005=\u20050.28) in the nortriptyline versus placebo comparison, and a mean change of \u22120.7 (\u22126.11 to 4.70,\n p<\/jats:italic>\n \u2005=\u20050.80) in the escitalopram versus placebo comparison. There was however a statistically significant difference in reduction of Patient Health Questionnaire-9 items scores between the nortriptyline and the placebo arm (\n p<\/jats:italic>\n \u2005=\u20050.01) but not the escitalopram compared to the placebo arm (\n p<\/jats:italic>\n \u2005=\u20050.33). There were no differences in adverse events, Movement Disorders Society Unified Parkinson\u2019s Disease Rating Scale scores or Montreal Cognitive Assessment scores. Descriptive analysis of health economic outcomes suggested no significant differences across time periods or groups.\n <\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n This trial was limited by low number of patients with depression in Parkinson\u2019s disease who could be recruited.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Future trials should concentrate on one rather than two medications to reduce the number of ineligible patients as well as the sample size. Alternatively, a three-arm comparison with a compound not currently available but with potential added benefit may also increase recruitment rate.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The ADepT-PD trial was terminated at the end of the pilot phase due to low recruitment. Only limited conclusions can be drawn as to the efficacy and safety of the active treatments.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n This trial is registered as NCT03652870.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16\/145\/01) and is published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 29, No. 57. See the NIHR Funding and Awards website for further award information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hfdo7575","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T11:02:31Z","timestamp":1736420551000},"page":"1-78","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Escitalopram and Nortriptyline on Depressive Symptoms in Parkinson\u2019s disease: the ADepT-PD RCT pilot"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9872-6680","authenticated-orcid":true,"given":"Anette","family":"Schrag","sequence":"first","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-953X","authenticated-orcid":true,"given":"Camille","family":"Carroll","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-8245","authenticated-orcid":true,"given":"Glyn","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8388-0776","authenticated-orcid":true,"given":"Marc","family":"Serfaty","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-3771","authenticated-orcid":true,"given":"Gordon","family":"Duncan","sequence":"additional","affiliation":[{"name":"NHS Lothian, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7830-1575","authenticated-orcid":true,"given":"Sophie","family":"Molloy","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-2883","authenticated-orcid":true,"given":"John","family":"Whipps","sequence":"additional","affiliation":[{"name":"PPI Representative, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-8100","authenticated-orcid":true,"given":"Blair","family":"McLennan","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2875-4029","authenticated-orcid":true,"given":"Jing Yi (Jessica)","family":"Weng","sequence":"additional","affiliation":[{"name":"Research Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-8934","authenticated-orcid":true,"given":"Rachael M","family":"Hunter","sequence":"additional","affiliation":[{"name":"Research Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-1257","authenticated-orcid":true,"given":"Caroline S","family":"Clarke","sequence":"additional","affiliation":[{"name":"Research Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-5740","authenticated-orcid":true,"given":"Nicholas","family":"Freemantle","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9402-8132","authenticated-orcid":true,"given":"Andrew","family":"Embleton-Thirsk","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2025,11]]},"reference":[{"key":"key2025111122382600_ref1-bib1","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1007\/s00198-016-3667-7","article-title":"Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort","volume":"27","author":"Carri\u00e8re","year":"2016","journal-title":"Osteoporos Int"},{"key":"key2025111122382600_ref2-bib2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"key":"key2025111122382600_ref3-bib3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Devos","year":"2008","journal-title":"Mov Disord"},{"key":"key2025111122382600_ref4-bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.parkreldis.2015.04.018","article-title":"Antidepressive treatments for Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"21","author":"Bomasang-Layno","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"key2025111122382600_ref5-bib5","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1017\/S0033291715001270","article-title":"Minimal clinically important difference on the Beck Depression Inventory-II according to the patient\u2019s perspective","volume":"45","author":"Button","year":"2015","journal-title":"Psychol Med"},{"key":"key2025111122382600_ref6-bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1192\/bjp.bp.110.091223","article-title":"Severity of depression and response to antidepressants: GENPOD randomised controlled trial","volume":"200","author":"Wiles","year":"2012","journal-title":"Br J Psychiatry"},{"key":"key2025111122382600_ref7-bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12883-022-02988-5","article-title":"Antidepressants Trial in Parkinson\u2019s Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson\u2019s disease","volume":"22","author":"Schrag","year":"2022","journal-title":"BMC Neurol"},{"key":"key2025111122382600_ref8-bib8","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"key2025111122382600_ref9-bib9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/070674370204700208","article-title":"Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine","volume":"47","author":"Vanderkooy","year":"2002","journal-title":"Can J Psychiatry"},{"key":"key2025111122382600_ref10-bib10","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"key2025111122382600_ref11-bib11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.21333","article-title":"Depression rating scales in Parkinson\u2019s disease: critique and recommendations","volume":"22","author":"Schrag","year":"2007","journal-title":"Mov Disord"},{"key":"key2025111122382600_ref12-bib12","volume-title":"Structure and Content of Clinical Study Reports (E3)","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"1995"},{"key":"key2025111122382600_ref13-bib13","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2019.3087","article-title":"Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement","volume":"321","author":"Juszczak","year":"2019","journal-title":"JAMA"},{"key":"key2025111122382600_ref14-bib14","doi-asserted-by":"crossref","first-page":"i5239","DOI":"10.1136\/bmj.i5239","article-title":"CONSORT 2010 statement: extension to randomised pilot and feasibility trials","volume":"355","author":"Eldridge","year":"2016","journal-title":"BMJ"},{"key":"key2025111122382600_ref15-bib15","doi-asserted-by":"crossref","first-page":"e068983","DOI":"10.1136\/bmj-2021-068983","article-title":"Visualising harms in publications of randomised controlled trials: consensus and recommendations","volume":"377","author":"Phillips","year":"2022","journal-title":"BMJ"},{"key":"key2025111122382600_ref16-bib16","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.socscimed.2008.05.015","article-title":"Valuing the ICECAP capability index for older people","volume":"67","author":"Coast","year":"2008","journal-title":"Soc Sci Med"},{"key":"key2025111122382600_ref17-bib17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"key2025111122382600_ref18-bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21730","article-title":"Home-based health promotion for older people with mild frailty: the HomeHealth intervention development and feasibility RCT","volume":"21","author":"Walters","year":"2017","journal-title":"Health Technol Assess"},{"key":"key2025111122382600_ref19-bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00019053-200826040-00001","article-title":"An overview of methods and applications to value informal care in economic evaluations of healthcare","volume":"26","author":"Koopmanschap","year":"2008","journal-title":"PharmacoEconomics"},{"key":"key2025111122382600_ref20-bib20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/mds.25919","article-title":"The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale","volume":"29","author":"Leentjens","year":"2014","journal-title":"Mov Disord"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/HFDO7575\/HFDO7575.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:12:22Z","timestamp":1762881142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/HFDO7575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":20,"alternative-id":["10.3310\/HFDO7575"],"URL":"https:\/\/doi.org\/10.3310\/hfdo7575","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"06-2018","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"12-2024","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"03-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}